Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.4M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
31.6M
-
Shares change
-
+3.58M
-
Total reported value, excl. options
-
$1.2B
-
Value change
-
+$171M
-
Number of buys
-
71
-
Number of sells
-
-21
-
Price
-
$37.93
Significant Holders of Spyre Therapeutics, Inc. - Common Stock (SYRE) as of Q1 2024
109 filings reported holding SYRE - Spyre Therapeutics, Inc. - Common Stock as of Q1 2024.
Spyre Therapeutics, Inc. - Common Stock (SYRE) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.6M shares
of 60.4M outstanding shares and own 52.41% of the company stock.
Largest 10 shareholders include FMR LLC (6.58M shares), PERCEPTIVE ADVISORS LLC (2.56M shares), RTW INVESTMENTS, LP (2.23M shares), VR Adviser, LLC (2.17M shares), COMMODORE CAPITAL LP (1.88M shares), Avoro Capital Advisors LLC (1.84M shares), Deep Track Capital, LP (1.21M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.11M shares), WELLINGTON MANAGEMENT GROUP LLP (813K shares), and FRANKLIN RESOURCES INC (742K shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.